| Pharmaceutical Information |
| Drug Name |
Besifloxacin |
| Drug ID |
BADD_D00256 |
| Description |
Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009. |
| Indications and Usage |
Treatment of bacterial conjunctivitis. Bacterial isolates that are susceptible to besifloxacin include: CDC coryneform group G; Corynebacterium pseudodiphtheriticum; Corynebacterium striatum; Haemophilus influenzae; Moraxella lacunata; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus hominis; Staphylococcus lugdunensis; Streptococcus mitis group; Streptococcus oralis; Streptococcus pneumoniae; Streptococcus salivarius* |
| Marketing Status |
Prescription |
| ATC Code |
S01AE08 |
| DrugBank ID |
DB06771
|
| KEGG ID |
D08872
|
| MeSH ID |
C522124
|
| PubChem ID |
10178705
|
| TTD Drug ID |
D00TRV
|
| NDC Product Code |
24208-446; 50090-1241 |
| Synonyms |
besifloxacin | 7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | besivance | besifloxacin hydrochloride | BOL-303224-A | 7-((3R)-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid |
|
| Chemical Information |
| Molecular Formula |
C19H21ClFN3O3 |
| CAS Registry Number |
141388-76-3 |
| SMILES |
C1CCN(CC(C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
